A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
about
sameAs
Interventions to improve antibiotic prescribing practices for hospital inpatientsInterventions to improve antibiotic prescribing practices for hospital inpatientsBTS Guidelines for the Management of Community Acquired Pneumonia in AdultsIdentifying research priorities on infections in older adults: proceedings of an interdisciplinary workshopHow to promote, improve and test adherence to scientific evidence in clinical practiceTools for outcome prediction in patients with community acquired pneumonia.Development and validation of a short questionnaire in community acquired pneumonia.Reducing door-to-antibiotic time in community-acquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis.Does physicians' case volume impact inpatient care costs for pneumonia cases?Reducing unnecessary hospital days to improve quality of care through physician accountability: a cluster randomised trial.Framework for the impact analysis and implementation of Clinical Prediction Rules (CPRs)A cluster randomized controlled trial of a clinical pathway for hospital treatment of heart failure: study design and population.Are the outcomes of clinical pathways evidence-based? A critical appraisal of clinical pathway evaluation research.The information and support needs of patients discharged after a short hospital stay for treatment of low-risk Community Acquired Pneumonia: implications for treatment without admissionEvaluation of pneumonia severity and acute physiology scores to predict ICU admission and mortality in patients hospitalized for influenza.Which patients with lower respiratory tract infections need inpatient treatment? Perceptions of physicians, nurses, patients and relativesOptimization of antibiotic use in hospitals--antimicrobial stewardship and the EU project ABS internationalManagement of intra-abdominal infections: recommendations by the WSES 2016 consensus conferenceRisk of heart failure after community acquired pneumonia: prospective controlled study with 10 years of follow-upRisk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission.Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule.Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm.Utilization review: can it be improved?Treatment and outcomes of community-acquired pneumonia at Canadian hospitalsNovel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adultsDo guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care?Validating hospital admission criteria for decision support in pneumoniaThe quality of the evidence base for clinical pathway effectiveness: room for improvement in the design of evaluation trialsImpact of clinical pathway on clinical outcomes in the management of COPD exacerbation.Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia.A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillationInterventions to improve antibiotic prescribing practices for hospital inpatients.Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections.Limited impact of a multicenter intervention to improve the quality and efficiency of pneumonia care.Improving the quality of pneumonia care that patients experience.Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infectionPractice guidelines and measurement: state-of-the-science.Changing needs of community-acquired pneumonia.Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study
P2860
Q24197807-0A69DC2D-1310-47A3-A767-459F36EE49CAQ24245936-D84C94B6-B9C0-4683-B42B-619C3D2A87FEQ24675547-0B0FEFE3-EA6E-4022-80FF-0A7BC91B260AQ24803393-680B041D-71E9-4DF3-AF61-86B00EFDDBB5Q24810512-AED015C3-05C2-4841-B184-B683498FCF2DQ30240254-660EFD23-5B55-4782-A0D6-9F16E5E5BBC9Q30478613-7109CD93-F09B-4D61-9B11-00123AC214B7Q30480791-C08A350C-1943-40CA-A6FE-D1B20649B4C1Q30490988-40E532AA-A6C6-41D2-AF39-6A9118F00EE0Q30536330-A9BD02B1-AFED-464F-AF5D-61613EB48D6DQ31038419-6E06B93A-F412-46E8-9838-AE5A27747AC1Q33305166-9CF02FA6-3D13-4BCC-ADD0-477B81417F21Q33309478-E919FE0B-D903-46B9-B40E-36B5D646D864Q33355839-0738E823-9B10-4D57-B516-9589E2EECE72Q33539788-CDD377B8-1BE7-4CD3-B877-63165687170DQ33540012-A4B2F7AA-0894-4E8C-B8BC-BF1557EBA9EDQ33637327-81A4506B-24B1-4915-8563-3F368922DD25Q33640559-C2436659-B2E2-4897-8C4F-251D7CF4ED2AQ33647377-04332301-341E-48EE-88DF-F612767161D9Q33686219-9312424F-3051-49D6-AEF9-364B2EA42D14Q33739099-3DB2815C-561B-4F7B-9A8D-07BB8B9630A3Q33771716-2E097687-CD8E-447B-B20E-6E219B2FDF68Q33888706-EB410591-E084-4FAC-9C01-EF74A2D8D118Q33976349-F4531B84-02FB-457A-990F-42A9D6F9FBD2Q34037816-9E4141E2-12C5-4310-8231-8FDFDD06D2BAQ34077164-D8FFF68F-96F7-4BFC-98FC-14F0582AA6B7Q34169255-A67447B4-7118-4B57-BC03-2E0B8715E54EQ34304275-02376145-B41E-41DC-883C-F67FD349F876Q34307968-E75C5CA7-F1C5-4F5F-8833-35E93E5A491FQ34315025-BCCDD1DE-B166-402F-B3D0-D292DFD89A00Q34417275-AD971E2F-12ED-45E4-BE41-A785B848BB5DQ34434368-D218FF56-9250-4919-9A97-A4CDE6A61E6CQ34550823-C44F29ED-5F59-42EB-B33B-F6FD50C3264FQ34789110-6F468D20-4EA2-409E-8AD4-0B87AED2212CQ34993302-3FE5A4A6-14E4-4FDB-B3F5-E85ECDB9719EQ35006712-7A8927AE-CC56-41E5-9877-935FB47CDEE5Q35017990-07F72677-9150-4D7C-AF78-E819A2ABA331Q35023282-8EED4291-1563-4F4C-8360-B7761DC18ED1Q35127530-CF8B5BA7-2C37-490B-967C-9BA99E903A81Q35128843-8FB9F77B-3827-425D-8D66-EF814FBD8082
P2860
A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@ast
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@en
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@nl
type
label
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@ast
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@en
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@nl
altLabel
A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia
@en
prefLabel
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@ast
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@en
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@nl
P2093
P3181
P356
P1476
A Controlled Trial of a Critical Pathway for Treatment of Community-Acquired Pneumonia
@en
A controlled trial of a critic ...... n Trial Assessing Levofloxacin
@en
P2093
M K Vandervoort
S L Wheeler
T J Marrie
Thomas J. Marrie
P3181
P356
10.1001/JAMA.283.6.749
P407
P577
2000-02-09T00:00:00Z